ABEO is undervalued; Market has NOT priced in FDA approval news.Looks like a good monthly or longer play for the following reasons:
1. Beginning to see elevated RVOL (although it is Pre) in the hundreds.
2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarte
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.80 USD
−63.73 M USD
0.00 USD
43.12 M
About Abeona Therapeutics Inc.
Sector
Industry
CEO
Vishwas Seshadri
Website
Headquarters
Cleveland
Founded
1974
FIGI
BBG00JVRN1C3
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
ABEOABEO stock presents one of the best opportunities in the US market, with target prices well above $100. It is an excellent stock for investors. Currently, the stock is in a weekly upward trend and has broken through a strong supply zone from which it had bounced multiple times before. Now, it is pul
ABEO Long PositionABEO has a nice Long setup .
Ma cross 32/72 strategy on weekly timeframe
with 1.5 reward to risk ratio .
Entry around 4.78 cents
Stop is at 3.63 cents , which is the low of the bottom of the candle of the MA cross
target is 6.50 cents
, indicators on chart is insane oscillator from T
Abeona Therapeutics Inc.** risky investment opportunity, $200m market capital **
Happy with the risk?
On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why?
1) Bullish divergences. Since the ‘great buy’ signal price action h
ABEO | Bullish All Year | LongAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
Watch this one!Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of 0H7R is 6.70 USD — it has decreased by −2.87% in the past 24 hours. Watch ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stocks are traded under the ticker 0H7R.
0H7R stock has risen by 22.87% compared to the previous week, the month change is a 48.07% rise, over the last year ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) has showed a 69.37% increase.
We've gathered analysts' opinions on ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) future price: according to them, 0H7R price has a max estimate of 25.00 USD and a min estimate of 17.00 USD. Watch 0H7R chart and read a more detailed ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stock forecast: see what analysts think of ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) and suggest that you do with its stocks.
0H7R reached its all-time high on May 18, 2018 with the price of 536.25 USD, and its all-time low was 2.25 USD and was reached on Feb 27, 2023. View more price dynamics on 0H7R chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0H7R stock is 6.36% volatile and has beta coefficient of 1.38. Track ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) there?
Today ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) has the market capitalization of 320.13 M, it has increased by 1.33% over the last week.
Yes, you can track ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
0H7R earnings for the last quarter are 0.50 USD per share, whereas the estimation was −0.35 USD resulting in a 243.68% surprise. The estimated earnings for the next quarter are −0.36 USD per share. See more details about ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) earnings.
ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 100.00 K USD. In the next quarter, revenue is expected to reach 0.00 USD.
0H7R net income for the last quarter is −9.29 M USD, while the quarter before that showed −30.27 M USD of net income which accounts for 69.30% change. Track more ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) financial stats to get the full picture.
No, 0H7R doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 4, 2025, the company has 136 employees. See our rating of the largest employees — is ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) on this list?
Like other stocks, 0H7R shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) stock shows the neutral signal. See more of ABEONA THERAPEUTICS INC COM USD0.01 (POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.